China’s leading COVID-19 vaccine maker applies for government license

By: |
November 25, 2020 8:46 PM

A representative of Sinopharm told state-run Global Times that the company had collected data from major countries such as UAE carrying out its vaccine clinical trials.

Earlier, the DBT had announced programmes for vaccine development and other COVID-related solutions, but this mission will be dedicated purely for development of vaccines, a DBT official said.ADB said more than 14.3 million positive cases have been identified in Asia and the Pacific, causing more than 2,00,000 deaths.

China’s leading vaccine producer Sinopharm announced on Wednesday that it has submitted an application to the Chinese authorities for marketisation of its COVID-19 vaccine based on data collected from countries carrying out its clinical trials.

A representative of Sinopharm told state-run Global Times that the company had collected data from major countries such as UAE carrying out its vaccine clinical trials.

Results are expected to be good but it is up to the Chinese authorities to make the decision as the government has strict review standards.

Sinopharm previously told the daily that it had reported the phase-III clinical data to China’s State Food and Drug Administration and was in the process of giving more detailed data, as requested.

The vaccine maker says it is in the final stage before marketisation, and is now making approval for the marketisation of the vaccine its top priority. It will be possible to release the phase three data in academic journals after the approval.

Our data is evaluated by relevant departments following protocols even stricter than in some Western countries, and we are in close communication with the WHO,” a representative of Sinopharm told the daily earlier.

A Chinese Foreign Ministry spokesman Zhao Lijian told a media briefing last week that five Chinese vaccine candidates are under clinical trials in countries including the UAE, Brazil, Pakistan and Peru.

Sinopharm, China’s state-owned vaccine producer, said on November 19 that its vaccine has been administered to about a million people under the government’s emergency use scheme.

In terms of emergency use, the vaccines were applied to nearly a million people and there has not been a single case of a serious adverse event. People have had only mild symptoms, Liu Jingzhen, chairman of China National Pharmaceutical Group (Sinopharm), said in an interview with a Sichuan-based digital media company that was published on Wednesday.

Until now, all our progress, from research to clinical trials to production and emergency use, we have been leading the world, he was quoted as saying by the Hong Kong-based South China Morning Post on last Thursday.
His comments came amid criticism that Chinese firms have not publicised the clinical data of its vaccine studies.

Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, Check out latest IPO News, Best Performing IPOs, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Financial Express is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.

Next Stories
1Vaccine hesitancy 39 per cent in Delhi-NCR: Survey
2Bird flu: FSSAI advises consumers not to eat undercooked chicken; says no need to panic
3Bird flu in poultry confirmed in few more places in Maharashtra, MP, Chhattisgarh